An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. - Wikidata - awgldk - TriplyDB

An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease.

An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease.

http://www.wikidata.org/entity/Q33943954

about

The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements Mitochondrial biology and Parkinson's disease Apaf-1 inhibitors protect from unwanted cell death in in vivo models of kidney ischemia and chemotherapy induced ototoxicity Effect of zinc and paraquat co-exposure on neurodegeneration: Modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats Human gene therapy and imaging in neurological diseases.Small molecule inhibitors of Apaf-1-related caspase- 3/-9 activation that control mitochondrial-dependent apoptosis.Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression.Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats.Advances in gene therapy for movement disorders.Neuroprotective gene therapy against acute neurological insults.Physiological and pathological roles of Apaf1 and the apoptosome.Gene therapy progress and prospects: Parkinson's disease.Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.Adeno-associated virus vectors: potential applications for cancer gene therapy.Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults.Molecular pathways of programmed cell death in experimental Parkinson's disease.Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.Innate and adaptive immunity for the pathobiology of Parkinson's disease Molecules that modulate Apaf-1 activity.MPTP mouse models of Parkinson's disease: an update.Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems.Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.Apaf1 inhibition promotes cell recovery from apoptosis.The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration Gene therapy targeting mitochondrial pathway in Parkinson's disease.BAG1 is neuroprotective in in vivo and in vitro models of Parkinson's disease.p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism.Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.Apocytochrome c blocks caspase-9 activation and Bax-induced apoptosis.Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection.Expression of BCL-2 via adeno-associated virus vectors rescues thalamic neurons after visual cortex lesion in the adult rat.Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice.Recombinant human granulocyte colony-stimulating factor protects against MPTP-induced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels.Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.Withania somnifera alleviates parkinsonian phenotypes by inhibiting apoptotic pathways in dopaminergic neurons.

P2860

Q24533492-12735D29-783F-49CE-9A95-FE068ACCFAB6 Q24632752-5DBD3347-53C7-4882-94B8-8DE2AE06AE87 Q26824090-CCB1314A-928C-44C3-9016-67A6562C1C9F Q28543956-59A9EA0B-CE17-47ED-81FE-D7E66E2A78F0 Q28572108-B16B31D8-00DC-4598-92C9-7B43C759F8B3 Q31023442-40740378-5D88-4190-8738-DC66440197BF Q33229065-F3218FCE-CAFC-4A09-8516-0A2C7C51149A Q33713384-75959080-A128-4288-8244-1C45DF13AF07 Q34245037-2E40AB07-EEAA-480B-8E41-E00F5C7EDCA8 Q34436780-E56CF7CC-5627-46B4-8983-B7977FA1FE89 Q34656049-CF32F562-BEE8-42B7-BA74-A9D0E4A90AEF Q35038275-B0F578BD-5E8F-40F0-87CD-959A979DD1F1 Q35136123-D0466454-BD7E-4682-B5B9-BAC802AD040A Q35206326-F5652EF2-A8FA-4ECB-9A30-C3C9E8A07EBB Q36150495-C017B6EE-539B-4063-956F-EEE5B011A500 Q36165834-EFF4013D-CFAE-40C8-B570-89891FAF56C2 Q36311189-69DB896F-3215-44CD-BD5F-A9CBE147AB03 Q36498768-8565BD4D-B3D6-4B07-BEA5-DD8DDEE9EA8F Q36690552-1DDBD867-8487-465B-934A-DAB77EE90AFB Q36961419-83F5DE17-401F-4155-9C3A-CC6EBD0E6A31 Q37198947-38F5737E-9788-4FE0-8B8F-E66FFEC58F5F Q37401280-BCFB5881-5BB5-4440-A621-CC26F642167D Q37680800-DE73053F-94FF-4A2E-97C4-F230714D4457 Q38070400-A754C412-A00F-4886-BF0D-C0DEA5DCA4D5 Q38492748-67D4A3D9-EDC0-454E-B65E-4731117A3FB7 Q38693732-35D10D50-BFBC-4559-AFD6-C92BA9CA2694 Q38836005-1EE13323-79BB-4500-8544-42B5D4C2C3D2 Q38860761-E8545E6F-B202-4622-8160-9B16B92938AD Q38957332-B84DF7A9-9EE6-4EB9-B17A-B7094B0ECA8F Q38967787-4D33B40C-1874-4E20-B52C-3CB46222DBD0 Q39401687-3741D17F-5258-431B-83EC-D9E7F330AA45 Q39527536-25FD3F6F-7062-45B3-8513-8501FF854659 Q40694903-8C91E718-EA6A-4BBE-90D1-FCDA4A219584 Q40726384-B431F4A8-E8D9-477C-B02C-A0585BBAB2C1 Q43982222-9B74121D-7B21-4C16-8DA2-F1467E9CE5C4 Q45071206-82C33F91-E8C0-43F8-9393-CAD3A28F8C8E Q48382225-81E9AABE-8DA8-4A1F-905D-161FE96E5E80 Q48547124-EED4E598-024C-4CA3-8551-040AC4E3E7CE Q50868527-BE2C6605-86C7-4F3A-9AE4-A44DBF35D4E1 Q54184805-3CBDA3E3-75F6-4AE4-A602-2D59091F118D

P2860

An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease.

http://www.wikidata.org/entity/Q33943954

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

An AAV-derived Apaf-1 dominant ...... erapy for Parkinson's disease.

@ast

An AAV-derived Apaf-1 dominant ...... erapy for Parkinson's disease.

@en

type

label

An AAV-derived Apaf-1 dominant ...... erapy for Parkinson's disease.

@ast

An AAV-derived Apaf-1 dominant ...... erapy for Parkinson's disease.

@en

prefLabel

An AAV-derived Apaf-1 dominant ...... erapy for Parkinson's disease.

@ast

An AAV-derived Apaf-1 dominant ...... erapy for Parkinson's disease.

@en

P1433

Q33943954-33DF86AE-6A6F-46E2-84B4-99B0FA2C3B0E

P1476

Q33943954-AE487C90-1CD8-4911-A335-31DB96B7DA6B

P2093

Q33943954-32438181-A592-4459-969C-C35074994907

Q33943954-3306268D-2B49-45A9-94BD-9FCD4795F84B

Q33943954-3BF110E6-5457-4E70-B4A0-8706DDEA55DF

Q33943954-583FEA9A-5ACD-4A01-B5F2-207AA5B5673F

Q33943954-5886CE29-1E8C-4D0B-818C-4602A86AD1DE

Q33943954-8895865C-7465-4230-9D2F-43E13C5FD286

Q33943954-92845656-453A-4C1A-BB7B-5AFC66EE2A5A

Q33943954-9A8A04D6-A8FD-44A2-AB2F-A0FB3E787871

Q33943954-9C1FE976-152D-4702-976D-B480659CDD9C

Q33943954-AA16E572-5017-4FFA-9542-EBBA0E9EDE63

P2860

Q33943954-00B93399-513A-47EA-AA83-DF4096179822

Q33943954-0CA98528-3F90-45D2-8F43-D4F4C4E248F1

Q33943954-19D127C3-F6FC-43FE-BFFB-2D548CA1FEEC

Q33943954-1DAC9C73-1F89-4BCE-80E5-6E112DCEAEEA

Q33943954-208E2220-2879-41B0-83B2-957A183C53A8

Q33943954-2214503C-EBDE-4225-8300-177784DAA327

Q33943954-232D7C20-DC09-482B-83AF-0222B2A56D9E

Q33943954-2A143053-3087-4B7E-AF65-2FDEFCB9E310

Q33943954-2EA5775A-60E0-4FB0-92E2-F0610B91BEB4

Q33943954-39E90C01-8E99-487A-89E7-F3E5D3DBDE88

P304

Q33943954-3A358C68-BF53-4B21-860B-2549068C7C19

P31

Q33943954-BC4BB39A-4CD4-4DA1-826A-024E49C273CA

P356

Q33943954-ED57FDEB-3DA7-474B-870A-A12CFC7FBBFD

P407

Q33943954-2A2C4539-C76B-4866-B1FD-DF5DD058158B

P433

Q33943954-2E4AA89A-D23A-4CA2-8CFB-DFE11F9FDC47

P478

Q33943954-A46D227E-011C-423C-B084-56A0D629D40E

P577

Q33943954-6C89AFC5-FF1E-4F15-BEAB-DC0930C97CA2

P5875

Q33943954-1AE0CAE1-AAF7-4BC6-893A-424E3D4F860D

P698

Q33943954-71B901F5-9B6D-4F89-A4D3-71CCA467EB38

P921

Q33943954-3DCC2036-8AA9-4529-937D-69F73A33E65E

Q33943954-67D42F83-0D8C-46BD-9DCC-65974CD950D2

P932

Q33943954-B992EBDF-D8B3-495F-A8C1-54B68E161940

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

An AAV-derived Apaf-1 dominant ...... erapy for Parkinson's disease.

@en

P2093

Hayakawa H

http://www.w3.org/2001/XMLSchema#string

Migita M

http://www.w3.org/2001/XMLSchema#string

Miura M

http://www.w3.org/2001/XMLSchema#string

Mizuno Y

http://www.w3.org/2001/XMLSchema#string

Mochizuki H

http://www.w3.org/2001/XMLSchema#string

Shibata M

http://www.w3.org/2001/XMLSchema#string

Shimada T

http://www.w3.org/2001/XMLSchema#string

Shimo-Nakanishi Y

http://www.w3.org/2001/XMLSchema#string

Suzuki A

http://www.w3.org/2001/XMLSchema#string

Tamayose K

http://www.w3.org/2001/XMLSchema#string

P2860

An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9

Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1

Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c

Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3

Efficient selection for high-expression transfectants with a novel eukaryotic vector

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization

Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3

Mitochondrial control of cell death

The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism.

P304

10918-10923

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.191107398

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11810235

http://www.w3.org/2001/XMLSchema#string

P698

11535810

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

58574

http://www.w3.org/2001/XMLSchema#string